Physician profile
Devabrata Ganguly
NPI 1225077274
$5,918.77
in general payments reported to CMS, 2019-2025
52 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $543 · 2021: $1,127 · 2022: $993 · 2023: $527 · 2024: $1,052 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053 · Education: $39.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.94 |
| Education | $39.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $623.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $484.86 | 2019-2025 | Verquvo, Pifeltro, Capvaxive |
| Viiv Healthcare Company | $448.51 | 2020-2025 | Cabenuva |
| Janssen Pharmaceuticals, INC | $412.65 | 2019-2024 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $351.58 | 2022-2024 | |
| Pfizer INC. | $326.54 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $270.00 | 2019-2020 | |
| Lilly USA, LLC | $259.16 | 2019-2025 | Jardiance, Kisunla, Amyvid |
| Rigel Pharmaceuticals, INC. | $250.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $235.26 | 2019-2024 | Airsupra |
| Idorsia Pharmaceuticals US INC | $233.72 | 2022-2024 | Quviviq |
| Amgen INC. | $209.58 | 2019-2024 | Repatha, Otezla, Evenity |
| Puma Biotechnology, INC. | $125.00 | 2021 | |
| Abbvie INC. | $122.88 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.76 | 2021-2025 | Jardiance |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devabrata Ganguly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.